Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
Ursula Kortmann(AstraZeneca (United Kingdom)), C. Blake Gilks(Fox Chase Cancer Center), Sophie Tully(AstraZeneca (United Kingdom)), Gavin Ha(AstraZeneca (United Kingdom)), Aaron Cranston(AstraZeneca (United Kingdom)), Jun Guan(Qingdao University), Mark J. O’Connor(AstraZeneca (United Kingdom)), Jessica N. McAlpine(University of British Columbia), David G. Huntsman(BC Cancer Agency), Yuzhuo Wang(BC Cancer Agency), Hui Xue, Alan Lau(AstraZeneca (United Kingdom)), Sharaz Shafait(AstraZeneca (United Kingdom))
Cited by 70
Related Papers
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
|PLoS Medicine|2010|1.1k
Patient-derived xenografts undergo mouse-specific tumor evolution
|Nature Genetics|2017|716